Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Mol Cancer Ther. 2010 Jan;9(1):236-45. doi: 10.1158/1535-7163.MCT-09-0767. Epub 2010 Jan 6.
Roscovitine and flavopiridol suppress cyclin-dependent kinase 7 (CDK7) and CDK9 activity resulting in transcription inhibition, thus providing an alternative mechanism to traditional genotoxic chemotherapy. These agents have been effective in slow or nonreplicative cell types. 8-Amino-adenosine is a transcription inhibitor that has proved very effective in multiple myeloma cell lines and primary indolent leukemia cells. The objective of the current work was to define mechanisms of action that lead to transcription inhibition by 8-amino-adenosine. 8-Amino-adenosine is metabolized into the active triphosphate (8-amino-ATP) in cells. This accumulation resulted in a simultaneous decrease of intracellular ATP and RNA synthesis. When the effects of established ATP synthesis inhibitors and transcription inhibitors on intracellular ATP concentrations and RNA synthesis were studied, there was a strong correlation between ATP decline and RNA synthesis. This correlation substantiated the hypothesis that the loss of ATP in 8-amino-adenosine-treated cells contributes to the decrease in transcription due to the lack of substrate needed for mRNA body and polyadenylation tail synthesis. RNA polymerase II COOH terminal domain phosphorylation declined sharply in 8-amino-adenosine-treated cells, which may have been due to the lack of an ATP phosphate donor or competitive inhibition with 8-amino-ATP at CDK7 and CDK9. Furthermore, 8-amino-ATP was incorporated into nascent RNA in a dose-dependent manner at the 3'-end resulting in transcription termination. Finally, in vitro transcription assays showed that 8-amino-ATP competes with ATP for incorporation into mRNA. Collectively, we have concluded that 8-amino-adenosine elicits effects on multiple mechanisms of transcription, providing a new class of transcription inhibitors.
罗司维司他和 flavopiridol 抑制周期蛋白依赖性激酶 7(CDK7)和 CDK9 的活性,导致转录抑制,从而提供了一种替代传统遗传毒性化疗的机制。这些药物在缓慢或非复制细胞类型中有效。8-氨基-腺苷是一种转录抑制剂,已被证明在多发性骨髓瘤细胞系和原发性惰性白血病细胞中非常有效。目前工作的目的是确定导致 8-氨基-腺苷转录抑制的作用机制。8-氨基-腺苷在细胞内代谢为活性三磷酸酯(8-氨基-ATP)。这种积累导致细胞内 ATP 和 RNA 合成同时减少。当研究已建立的 ATP 合成抑制剂和转录抑制剂对细胞内 ATP 浓度和 RNA 合成的影响时,ATP 下降与 RNA 合成之间存在很强的相关性。这种相关性证实了以下假设:8-氨基-腺苷处理的细胞中 ATP 的丧失导致转录减少,原因是缺乏 mRNA 体和多聚腺苷酸尾合成所需的底物。8-氨基-腺苷处理的细胞中 RNA 聚合酶 II COOH 末端结构域磷酸化急剧下降,这可能是由于缺乏 ATP 磷酸供体或 8-氨基-ATP 与 CDK7 和 CDK9 的竞争性抑制。此外,8-氨基-ATP 以剂量依赖的方式掺入新生 RNA 的 3'-末端,导致转录终止。最后,体外转录测定表明 8-氨基-ATP 与 ATP 竞争掺入 mRNA。总的来说,我们得出结论,8-氨基-腺苷对转录的多个机制产生影响,提供了一类新的转录抑制剂。